ATR-X Syndrome Protein Targets Tandem Repeats and Influences Allele-Specific Expression in a Size-Dependent Manner  by Law, Martin J. et al.
ATR-X Syndrome Protein Targets Tandem
Repeats and Influences Allele-Specific
Expression in a Size-Dependent Manner
Martin J. Law,1,8 Karen M. Lower,1,8 Hsiao P.J. Voon,1 Jim R. Hughes,1 David Garrick,1 Vip Viprakasit,3
Matthew Mitson,1 Marco De Gobbi,1 Marco Marra,7 Andrew Morris,4 Aaron Abbott,4 Steven P. Wilder,5
Stephen Taylor,2 Guilherme M. Santos,6 Joe Cross,1 Helena Ayyub,1 Steven Jones,7 Jiannis Ragoussis,4
Daniela Rhodes,6 Ian Dunham,5 Douglas R. Higgs,1 and Richard J. Gibbons1,*
1Medical Research Council Molecular Haematology Unit
2Computational Biology Research Group
Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
3Department of Paediatrics, Faculty of Medicine, Siriaj Hospital, Mahidol University, Bangkok 10700, Thailand
4The Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, UK
5European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK
6Structural Studies Division, Medical Research Council, Laboratory of Molecular Biology, Cambridge CB2 0QH, UK
7BCCA Genome Sciences Centre, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada
8These authors contributed equally to this work
*Correspondence: richard.gibbons@imm.ox.ac.uk
DOI 10.1016/j.cell.2010.09.023SUMMARY
ATRX is an X-linked gene of the SWI/SNF family,
mutations in which cause syndromal mental retarda-
tion and downregulation of a-globin expression.
Here we show that ATRX binds to tandem repeat
(TR) sequences in both telomeres and euchromatin.
Genes associated with these TRs can be dysregu-
lated when ATRX is mutated, and the change in
expression is determined by the size of the TR, pro-
ducing skewed allelic expression. This reveals the
characteristics of the affected genes, explains the
variable phenotypes seen with identical ATRXmuta-
tions, and illustrates a new mechanism underlying
variable penetrance. Many of the TRs are G rich
and predicted to form non-B DNA structures (in-
cluding G-quadruplex) in vivo. We show that ATRX
binds G-quadruplex structures in vitro, suggesting
a mechanism by which ATRX may play a role in
various nuclear processes and how this is perturbed
when ATRX is mutated.INTRODUCTION
Although it is known that proteins of the Swi/Snf family are
required to facilitate a wide range of nuclear processes (e.g.,
replication, recombination, repair, transcription), the mecha-
nisms by which they operate in vivo are poorly understood (Flaus
et al., 2006). One such widely expressed protein (ATRX) was first
identified when it was shown that mutations in the X-linked gene
(ATRX) caused a form of syndromal mental retardation, withmultiple developmental abnormalities characteristically associ-
ated with a thalassaemia (ATR-X syndrome) (Gibbons et al.,
1995). To date 127 disease-causing mutations have been found,
most of which are located in two highly conserved domains of
the ATRX protein (Gibbons et al., 2008). At the N terminus these
lie within a globular domain (similar to that found in DNMT3 and
DNMT3L, the so-called ADD domain) including a plant homeo-
domain (PHD), which most probably binds the N-terminal tails
of histone H3 (Argentaro et al., 2007). At the C terminus there
are seven helicase subdomains that identify ATRX as a member
of the SNF2 family of chromatin-associated proteins (Figure 1A).
Although many of these proteins have been shown to remodel,
remove, or slide nucleosomes using in vitro assays, ATRX is
most closely related to a subgroup (including RAD54 and
ARIP4) that, despite acting as ATP-driven molecular motors,
perform poorly in such canonical assays, suggesting that they
have related but different chromatin-associated functions (Xue
et al., 2003 and unpublished data).
Some clues to the role of ATRX in vivo have come from
studying its distribution in the nucleus, the proteins with which
it interacts, and the effects of mutations. Using indirect immuno-
fluorescence, ATRX is found at heterochromatic repeats, at
rDNA repeats, at telomeric repeats, and within PML bodies,
which themselves are often associated with heterochromatic
structures including telomeres (Gibbons et al., 2000; McDowell
et al., 1999; Xue et al., 2003). Two robust protein-protein interac-
tions have been described. The first occurs with DAXX (Xue et al.,
2003) (a protein that is also found in PML bodies), which has
been implicated in both pro- and antiapoptotic pathways. The
second interaction occurs with HP1a and HP1b, proteins that
are widely associated with heterochromatin, including the telo-
mere (Berube et al., 2000). It has also been shown that mutations
in ATRX are consistently associated with alterations in theCell 143, 367–378, October 29, 2010 ª2010 Elsevier Inc. 367
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Figure 1. Validation of ATRX ChIP Protocol
(A) Immunoblots of protein extracts from ATR-X patient and normal control lymphoblastoid cell lines using ATRX N- and C-terminal antibodies. The ATR-X patient
harbors an ATRX C-terminal deletion mutation affecting the C-terminal antibody epitope. Schematic diagram of ATRX shows protein isoforms, antibody epitope
regions, and conserved domains.
(B) The ATRX C-terminal antibody crosslinked to protein A-Sepharose was used to immunopurify ATRX from EBV cells. Eluted protein was analyzed by western
blot probed with the N-terminal mouse monoclonal ATRX antibody, 39f. The mock control lane contains sample immunopurified using normal rabbit IgG.
(C) Q-PCR analysis of ATRX ChIP at the major ribosomal RNA gene locus in erythroblast (n = 4) and Hep3B (n = 3). Error bars show standard deviations. Diagram
of the ribosomal RNA gene locus shows positions of rRNAs (red boxes), the promoter (arrow), and the Q-PCR primers (boxes above line).
(D) Direct mapping of human ATRX, SCL, and YY1 ChIP-seq reads to simple and interspersed repeats. Selected representative data are shown. For the complete
dataset, see Table S1.
(E) Direct mapping of ATRX ChIP-seq sequence reads to mouse simple and interspersed repeats.
See Figure S1 for further validation of the specificity of the ATRX ChIP.pattern of DNA methylation at such repeat sequences (rDNA,
interstitial heterochromatic repeats, and subtelomeric repeats)
(Gibbons et al., 2000).
Recently, an important link has been established between
these observations and more functional studies. First, it has
been shown that ATRX and HP1 localize to the telomeres of
chromosomes in mouse embryonic stem cells (ESCs) (Wong
et al., 2010). Second, it has been shown that ATRX localizes to
telomeres in synchrony with the histone variant H3.3. Using
immunoprecipitation it was shown that ATRX and its partner368 Cell 143, 367–378, October 29, 2010 ª2010 Elsevier Inc.DAXX specifically interact with H3.3, which is found to be asso-
ciated with both active and inactive genes, regulatory elements,
and telomeres (Goldberg et al., 2010). It has recently been shown
that DAXX is an H3.3-specific chaperone (Drane´ et al., 2010;
Lewis et al., 2010), and in the absence of ATRX, H3.3 is no longer
recruited to telomereswhereas recruitment to the interstitial sites
that were analyzed appeared to be unaffected (Goldberg et al.,
2010). These observations suggest that ATRX plays an important
role in establishing or maintaining the chromatin environment of
telomeres and subtelomeric regions where it facilitates histone
replacement with the H3.3 variant (Drane´ et al., 2010; Lewis
et al., 2010).
Although these observations have provided new insight into
the potential role of ATRX at heterochromatic regions of the
genome, they have not identified the euchromatic targets of
ATRX and have not addressed the role of ATRX in regulating
gene expression. To date the only human genes whose expres-
sion is known to be affected by ATRX mutations lie in the
a-globin gene cluster (Gibbons et al., 1991). Although clearly
related to the b-globin cluster throughout evolution, ATRX muta-
tions do not affect b-globin expression. It has been noted that the
structure (e.g., GC content, repeat density, gene density),
nuclear organization (e.g., nuclear position, relationship to
chromosome territory, relationship to heterochromatin), and
epigenetic environment (e.g., timing of replication, chromatin
modification, DNA methylation) associated with these two
clusters are radically different (Higgs et al., 1998). Most notably
the human a-globin cluster lies very close to the telomere of
chromosome 16. It has previously been suggested that ATRX
is targeted to specific regions of the genome defined by their
genomic organization and/or chromatin structure. Thus muta-
tions in ATRX may affect one type of chromosomal region
(e.g., containing the a-globin genes) but not another (e.g., con-
taining the b-globin genes).
Here we have established the genome-wide distribution of the
ATRXprotein in bothmouseandhumancells.Wehave confirmed
that ATRXbinds directly tomouse telomeres and also shown that
ATRX is enriched at the telomeres and subtelomeric regions of
human chromosomes. Chromatin immunoprecipitation (ChIP)
sequencing identified 917 targets in primary human erythroid
cells (in which the globin genes are expressed) and 1305 targets
inmouse ESCs. Themost prominent feature of the targets in both
human and mouse is the presence of variable number tandem
repeats (VNTRs), which in many (but not all) cases are G and C
rich and contain a high proportion of CpG dinucleotides. Of
particular interest we show that, when ATRX function is compro-
mised in ATR-X syndrome, the degree of perturbation in gene
expression is related to the size of the TR, and this may lead to
monoallelic expression. These findings explain the variable
phenotypes seen in patients with identical ATRX mutations and
provide a new mechanism underlying variable penetrance. A
common theme shared by telomeres and many of the subtelo-
meric targets of ATRX is their potential to form G-quadruplex
(G4) DNA structures. Here we show that ATRX binds G4 DNA
in vitro, suggesting a common mechanism by which ATRX may
influenceawide rangeof nuclear processes in the telomeric, sub-
telomeric, and interstitial regions of mammalian chromosomes.
RESULTS
Validation of an ATRX ChIP Protocol
with rDNA as a Target
Domain structure, interaction partners, and biochemical activity
currently implicate ATRX in the regulation of transcription via a
physical interaction with chromatin. To date, ATRX has been
implicated in histone H3.3 deposition at telomeres, but little is
known about ATRX function away from telomeres because no
direct ATRX target genes have been described. To addressthis, an ATRX ChIP assay was developed using the ribosomal
gene loci (rDNA) as the first candidate targets. The rDNA loci
were chosen because immunofluorescence studies have previ-
ously shown that, in mitotic cells, ATRX is consistently found
on the short arms of the acrocentric chromosomes in human
colocalizing with the rDNA loci (McDowell et al., 1999); rDNA
also becomes hypomethylated at CpG dinucleotides in primary
peripheral blood mononuclear cells (PBMCs) from patients
with ATR-X syndrome (Gibbons et al., 2000).
ChIP analysis was performed with an ATRX antibody that
recognizes a C-terminal epitope only present in the full-length
ATRX isoform (Figure 1A). Western blot was used to confirm
that this antibody immunoprecipitates ATRX with detection
using an independent antibody (Figure 1B). ATRX ChIP enrich-
ment at rDNA was measured in primary erythroblasts and
Hep3B cells (Figure 1C). Consistent with its ubiquitous expres-
sion profile, ATRX binds rDNA in both cell types tested. It was
of interest that the maximal binding of ATRX occurs at the
transcribed region of the locus that is very rich in G and CpG
nucleotides. These observations confirm the specificity of the
ATRX C-terminal antibody, validate the ChIP assay, and identify
the ribosomal genes as direct ATRX targets.
ATRX Binds G-Rich Telomeric and Subtelomeric
Repetitive DNA
Having validated the ATRX ChIP protocol, we next addressed
whether, in addition to rDNA, other putative targets (heterochro-
matic repeats) identified by indirect immunofluorescence were
similarly bound by ATRX. To accomplish this, we took a ChIP-seq
approach using Illumina high-throughput, short read sequencing
to analyze primary human erythroid cells and mouse ESCs.
ATRX ChIP DNA from human primary erythroid cells was se-
quenced alongside sonicated input DNA as a control. The short
read mapping protocol used for ChIP sequencing (see below)
routinely discards nonunique genomic matches, precluding
analysis of direct binding to repeat sequences. To overcome
this, we interrogated the ATRX ChIP read library for perfect se-
quence matches to a variety of tandem and interspersed repeat
sequences. As a negative control, we used ChIP-seq data for
YY1 and SCL, transcription factors that have no known role at
heterochromatic repeats. YY1 and SCL ChIP DNA both showed
low enrichment of telomeric and nontelomeric satellite se-
quences (Figure 1D and Table S1 available online). ATRX ChIP
DNA showed striking enrichments for the G-rich telomeric
(TTAGGG)n repeats (16-fold relative to input DNA) and telo-
mere-associated repeats (10-fold relative to input) (Figure 1D
and Table S1). Similar results were obtained from the analysis
of ChIP-seq data from mouse ESCs (Figure 1E and Table S1).
Further confirmation of the specificity of the ATRX ChIP was
demonstrated by showing that ATRX enrichment was abolished
when ChIP was performed in mouse ESCs in which full-length
ATRX was knocked out (Figure S1).
These data therefore show that previously described immuno-
fluorescence studies reflect the binding of ATRX to telomeric
and subtelomeric repeat sequences. The presence of ATRX at
the subtelomeric TAR1 repeats is consistent with previous
observations that DNA methylation at subtelomeric repeats is
altered in patients with ATR-X syndrome (Gibbons et al., 2000).Cell 143, 367–378, October 29, 2010 ª2010 Elsevier Inc. 369
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Figure 2. Genome-wide Comparison of Human and Mouse ATRX-Binding Site Characteristics
(A) Pie charts show the location of human and mouse ATRX-binding sites relative to genes.
(B) The proportion of human andmouse ATRX peaks overlapping with the twomost common classes of human ATRX-binding sites, TRs and CpG islands (CpGi).
See also Figure S2C for genomic features associated with peaks.
(C) Ideograms showing the relative distribution of ATRX-binding sites across all human and mouse chromosomes. Each column represents the total number of
ATRX peaks within nonoverlapping 1/500 divisions of all chromosome arms. The zoomed panels show the telomeric region, overlayed with the mean %G+C
content of all tandem repeats throughout the same regions, for the respective human andmouse chromosomes. The sharp peak of subtelomeric targets inmouse
represents clusters of (TTAGGG)n adjacent to the telomeres of a subset ofmouse chromosomes. See also Figure S2E for the distribution of TRs and Refseq genes
near telomeres.
See also Figure S2A for validation of targets by Q-PCR, Figure S2B for examples of ATRX-binding sites, Figure S2D for trinucleotide content of DNA sequence
underlying peaks, Figure S3A for histone modifications associated with peaks, and Figure S3B for histone H3.3 distribution associated with ATRX peaks.Genome-wide Targets of ATRX Include CpG Islands
and G-Rich Tandem Repeats
Having established that ATRX binds G-rich repetitive elements
associated with rDNA, telomeres, and subtelomeric repeats,
ATRX ChIP and input sequence reads were aligned to the
genome if five or fewer matches were detected (allowing for
three base-pair mismatches). Peak calling was performed on
the ATRX ChIP-seq alignments using an input correction penalty
to deplete peaks overlying enrichments of input reads. The input
correction penalty effectively eradicated many peaks overlying
DNA where there were differences in copy number between370 Cell 143, 367–378, October 29, 2010 ª2010 Elsevier Inc.the reference genome and the sequenced genome (e.g., at
pericentromeric satellite DNA).
Using these criteria in primary human erythroid cells we
identified 917 ATRX-binding sites genome-wide. The ChIP
enrichment at 14 sites (chosen to represent the different classes
of targets discussed below) was validated using Q-PCR. ATRX
binding at most of these sites was enriched above background
levels 10/14 (false discovery rate 4/14; Figure S2A). Of the 917
ATRX peaks called, approximately a third (324) were intergenic,
a third were present at promoter regions (326), and a third were in
the bodies of genes (267) (Figure 2A). All peaks were then
examined for overlap with annotated genomic sequence
features (Figures S2B and S2C). Two striking observations arise
from this analysis: first, irrespective of location relative to genes,
human ATRX-binding sites commonly coincide with CpG islands
(Figure 2B); second, the predominant sequence feature that
ATRX binds in gene bodies and intergenic regions is tandem
repetitive DNA (Figure 2B and Figure S2C). Analysis of ATRX
binding in mouse ESCs (Figure 2A) identified a larger number
of ATRX targets (1305) and showed a similar enrichment at
TRs but less so at CpG islands (Figure 2B) (which occur much
less frequently in the mouse genome) (Waterston et al., 2002).
As the tandem repetitive ATRX targets at rDNA and telomeres
are G rich, we reasoned that this might be a common property of
other ATRX-bound TRs. To test this we calculated the tri-nucle-
otide sequence content of ATRX-bound tandem repetitive
targets. ATRX-bound TRs in both mouse and human are signifi-
cantly enriched for G and C and CpG, and they are depleted in
A- and T-containing trinucleotides relative to randomly selected
control repeats (Figure S2D and data not shown).
These findings are consistent with the observation that in
human cells, many ATRX-bound promoters are associated
with CpG islands. Genome-wide analysis (in human) showed
that there are no chromatin modifications consistently associ-
ated with binding of ATRX. Chromatin marks found at the
promoter and intragenic and intergenic binding sites show the
characteristic chromatin modifications associated with such
features (Figure S3A). Together the data suggest that ATRX
interacts predominantly with G and C and CpG-rich sequences
contained within TRs and promoters.
The Distribution of ATRX-Binding Sites Differs
between Human and Mouse, Reflecting the Different
Distributions of G-Rich Tandem Repeats
Initial analysis of the human ChIP-seq data suggested that ATRX
targets may be clustered at subtelomeric regions of the genome
(Figure 1D). This was confirmed when the proportions of ATRX-
binding sites were plotted as a function of their distance from the
nearest telomere (pooling data for all telomeres) (Figure 2C).
However, it has previously been shown that in humans, GC
content, CpG density, G-rich minisatellites, and gene density
are all increased in subtelomeric regions of the genome, and
this was confirmed here (Figure 2C and Figure S2F). In fact,
the distribution of ATRX targets in humans appears largely to
reflect the increase in GC content and G-rich TRs observed
toward telomeres rather than increased gene or general TR
density (Figure 2C and Figure S2E).
To explore this further, we compared the data from human
with those from mouse, a species with less extremes of GC
content and a different distribution of G-rich repeats (Waterston
et al., 2002). In mouse, the GC content of TRs is not increased
toward telomeres but is more evenly distributed across each
chromosome (Figure 2C). Although themajority of mouse targets
are associated with CpG islands or TRs (as in human), themouse
ATRX targets are less concentrated at telomeres (Figure 2C).
This more even distribution of ATRX targets in mouse is consis-
tent with the more even distribution of GC content and G-rich
repeats in mouse compared to human (Figure 2C). These find-
ings focus attention on the fact that ATRX appears to bindmany G-rich TRs in different chromosomal environments rather
than genes within subtelomeric regions per se.
Analysis of H3.3 Distribution in the Absence of ATRX
Telomeres are a site of rapid nucleosomal turnover as demon-
strated by the incorporation of histone H3.3 (Goldberg et al.,
2010). Furthermore, it has recently been shown that ATRX
recruits the histone H3.3-specific chaperone DAXX and facili-
tates H3.3 deposition at telomeres and pericentric DNA (Drane´
et al., 2010; Lewis et al., 2010). In order to see whether H3.3 co-
localized with ATRX at its target sequences (predominantly TRs,
Figure 2B), data for the H3.3 distribution in mouse ESCs (Gold-
berg et al., 2010) were reanalyzed to determine the distribution
of H3.3 at ATRX-binding sites (Figure S3B). Peaks of H3.3 are
observed at genic and intergenic ATRX sites. ATRX has previ-
ously been shown to be required for H3.3 deposition at telo-
meres but not at promoters and transcription factor-binding sites
(Goldberg et al., 2010). In order to see if the H3.3 distribution
at these sites is dependent on ATRX, the patterns of H3.3 for
Atrxflox and Atrxnull mouse ESCs were compared. The distribu-
tion of H3.3 is only subtly perturbed at ATRX-binding sites in
gene bodies and intergenic sites (Figure S3B) with a slight dimi-
nution of the peak and increased signal in the adjacent
sequence. If ATRX is required for H3.3 incorporation it may be
only at a subset of these targets.
Analysis of Expression of ATRX Targets when ATRX
Is Mutated
Although we initially identified the human ATRX targets in
erythroid cells, because many of the affected genes are widely
expressed, we compared their expression in Epstein-Barr virus
(EBV)-transformed lymphocytes from normal individuals (n = 19)
with expression in EBV cells from individuals harboring natural
mutations in the ATRX gene (n = 23). Twenty ATRX targets
(expressed in EBV-transformed lymphocytes) were chosen for
analysis, including 9 ATRX promoter-binding targets and 11
tandem repetitive gene body targets. Four ATRX targets were
significantly altered in expression in ATR-X patients relative to
normal controls: NME4, SLC7A5, and RASA3 were downregu-
lated, whereas GAS8 was upregulated (Figure 3). Interestingly
all four novel targets contained tandem repetitive ATRX-binding
sites, whereas none of the nonrepetitive, promoter-binding site
target genes was affected. These data suggest that when
ATRX alters gene expression, this involves an interaction with
TRs associated with its target genes.
ATRX Exerts an Effect on Target Gene Expression via
an Interaction with G-Rich Repeats
To examine the role of ATRX in regulating gene expression in
detail, we analyzed the subtelomeric region of chromosome 16
(16p13.3), which contains two ATRX targets (a-globin and
NME4), both of which are downregulated in ATR-X syndrome.
ChIP-seq analysis of this area was confirmed by ChIP-chip anal-
ysis (Figures 4A and 4B and Figure S4A). With this approach,
three consistent peaks of ATRX binding were seen in primary
erythroid cells. A small but reproducible enrichment was seen
at the probe closest to the telomere (telomeric repeats were
not included on the array). In erythroid cells, a broad region ofCell 143, 367–378, October 29, 2010 ª2010 Elsevier Inc. 371
Figure 3. Dysregulation of ATRX Targets Genes
Q-PCR analysis of gene expression of ATRX ChIP target genes in ATR-X patient (n = 21) and normal control (n = 19) lymphoblastoid cDNAs. Gray dots represent
control samples. Black dots represent genes unaffected in patient samples. Data are normalized to the mean values of the control samples. Black bars represent
mean values. Red dots show genes affected in patient samples. p values are for a two-tailed Student’s t test. The presence of a TR or CpG island underling the
ATRX-binding sites is indicated.enrichment was seen across all the a-like globin genes with
maximum binding just upstream of the HBM globin gene. A third
peak was seen at the gene encoding a nucleoside kinase, NME4
(Figure 4A and Figure S4A). When we used Q-PCR (Figures S4B
and S4C), we noted that all peaks of ATRX binding localized at or
very close to regions of G-rich tandemly repetitive DNA. The sub-
telomeric peak shows an enrichment lying 150 bp from the
start of the telomeric satellite repeats (TTAGGG)n (Figure S4B).
The maximum peak of binding in the a-globin locus lies within
a VNTR (CGCGGGGCGGGGG)n 1 kb upstream from the HBM
promoter, called jz VNTR (Figures S4B and S4C). The peak at
NME4 is centered on an imperfect VNTR (CCCGG
CCCCCCCA)n within the first intron of the gene (Figures S4B
and S4C).
It has been previously shown that expression of RNA from the
HBA1 and HBA2 globin genes is downregulated in patients with
the ATR-X syndrome (Wilkie et al., 1990). However, maximal
ATRX binding occurs not at theHBA genes but in close proximity
to the HBM and NME4 genes. We therefore took an unbiased
approach using RT-PCR to measure expression of all 16 genes
in the 500 kb region in normal individuals (n = 19) and those
proven to have ATR-X syndrome (n = 20) (Figure 4C). Globin
gene expression was analyzed using cDNA derived from
erythroid cells, and other genes were analyzed using cDNA
from EBV cell lines (nonglobinmRNAs are of very low abundance
in erythrocytes). The most consistently and severely downregu-
lated genes (HBM and NME4) were those associated with the
greatest peaks of ATRX enrichment (Figures 4B and 4C). It was
of interest that other significantly downregulated genes (HBA2,
HBA1, HBQ, and DECR2) lie adjacent to these severely affected
genes. Furthermore, the degree of downregulation of each a-like
globin (HBM > HBA2 = HBA1 > HBQ) gene is related to its
proximity to the major peak of ATRX binding 1 kb upstream
from the HBM gene.372 Cell 143, 367–378, October 29, 2010 ª2010 Elsevier Inc.This observation explains the a thalassaemia seen in ATR-X
syndrome and why a-globin and not b-globin expression is
perturbed, as only the former locus is associated with G-rich
VNTRs (Higgs et al., 1998).
The Perturbation in Gene Expression Is Related
to the Size of the Associated Tandem Repeat
In ATR-X syndrome, a-globin RNA expression is often downre-
gulated, but affected individuals show different degrees of
repression (Figure 4C). This gives rise to different degrees of
a thalassaemia and is reflected by varying proportions of red
cells containing HbH inclusions, ranging from 0%–30%
(Gibbons et al., 2008). Importantly, such variation is seen
between individuals with the same ATRX mutation (Figure S5A)
and occurs both within and between affected families. How-
ever, for any individual, the level of HbH is relatively constant
throughout life. If the downregulation of a-globin expression in
ATR-X syndrome resulted from a negative effect due to a TR
then one might predict that the effect would be more extreme
when the repeat is increased in size. The jz VNTR is highly poly-
morphic. The size of the TR alleles was measured in 43 ATR-X
individuals, and the average size in an individual was plotted
against the level of HbH inclusions observed. A significant
correlation (r value = 0.58; p = 0.0002) was seen between the
level of inclusions (reflecting the degree of a thalassaemia)
and the size of the TR (Figure 5A and Figure S5B). jz VNTR
lies within a block of linkage disequilibrium (Figure S5C and
Table S3); polymorphisms within this block also show a correla-
tion with the number of cells containing HbH inclusions. In
contrast with jz VNTR, another VNTR within this block,
30HVR, showed a low correlation between size and the severity
of a thalassaemia (Figure S5B). Given the rapid evolution of
VNTRs relative to the background haplotype, the strong corre-
lation associated with the jz VNTR strongly supports the
A 
B
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Figure 4. ATRX Interacts with the a-Globin Locus and Influences Gene Expression
(A) Microarray analysis (black bars) of ATRX ChIP DNA enrichment across the 500 kb terminal region of chromosome 16p containing the a-globin genes
and surrounding ubiquitously expressed genes. ATRX ChIP DNA from erythroblasts (n = 4), fibroblasts (n = 1), and Hep3B (n = 2) cells were analyzed as well
as erythroblasts immunoprecipitated with control IgG (n = 2). Representative data are shown. See Figure S4A for full dataset for erythroblasts.
(B) ChIP-seq analysis of erythroblast ATRX ChIP and input DNA using Illumina short-read sequencing. Graphs are a 50 bp sliding window of mapped reads.
Black bars show peak calls.
(C) Q-PCR analysis of gene expression across the a-globin gene locus in ATR-X patient (n = 20) and normal control (n = 19) cDNAs (from erythroid cells for the
globin genes or lymphoblastoid cells for other genes). Expression wasmeasured relative to GAPDH and themean expression values for the normal controls were
set to 100%. Red bars represent means of ATR-X patient expression and p values are for a two-tailed t test. See Figures S4B and S4C for validation of targets by
Q-PCR and mapping of peaks to G-rich VNTRs.
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Figure 5. ATRX-Binding Variable Number
Tandem Repeats Act as Length-Dependent
Negative Regulators of Gene Expression
When ATR-X Is Mutated
(A) jz VNTR length was measured in ATR-X
patients with a thalassaemia (n = 42) using PCR
and agarose gel electrophoresis and plotted
against the degree of a thalassaemia as measured
by% red cells showing Haemoglobin H inclusions.
See Figure S5B to compare correlation of VNTR
size and % red cells showing Haemoglobin H
inclusions for jz VNTR and 30HVR. Spearman
ranked correlation r value = 0.58, p value =
0.0002. See also Figure S5A for variable severity
of a thalassaemia in ATR-X syndrome, see Figur-
e S5C and Table S3 for a-globin locus haplotype
and linkage analysis.
(B) Q-PCR-based allelic discrimination assay was
used to determine the ratios of each NME4 allele
present in both genomic DNA and cDNA from
controls and ATR-X patients. The y axis is the ratio
of A:Gallele (SNP rs14293), shown on a logarithmic
scale. For control cDNA samples, the ratio of A:G
allele expression is 0.70 to 1.30, mean = 1.0,
n = 13. For ATR-X cDNA samples, the ratio of
A:G allele expression is 0.24 to 2.37,
mean = 0.84, n = 17. F-test p value = 5.74 3
105. For the green datapoint, the larger VNTR is
linked to the G allele; for the red datapoints, the
larger VNTR is linked to the A allele. For the blue
datapoint, alleles could not be discriminated
based on VNTR size.
(C) Schematic representation of the exon/intron
structure of NME4. White boxes represent exons.
PCR amplicons are shown as generated from
genomic DNA and cDNA. The presence of a poly-
morphic XhoI site generated by SNP rs14293 in
NME4 exon 4 is shown,which allowsallelic discrim-
ination by PCR amplification followed by an XhoI
restriction digest assay, the restriction site being
present in the G allele and abolished in the A allele.
(D) Results show monoallelic expression of NME4
in two individuals with ATR-X syndrome.proposal that it is directly responsible for the variability seen in
the level of HbH inclusions.
The effect of TR size was further examined at the NME4 locus.
Again the TR is highly polymorphic; in this case the presence
of an expressed A/G single-nucleotide polymorphism (SNP) al-
lowed us to determine the effect of the TR size on allele-specific
expression. In ATR-X cases informative for the expressed SNP,
the most downregulated allele is always in cis with the larger TR
(Figures 5B and 5C). In some cases the expression was monoal-
lelic (Figure 5D).
ATRX Targets Have the Potential to Form G4 DNA,
and ATRX Binds to G4 DNA Structures
Tandem repetitive sequences can take up a range of non-B DNA
conformations (reviewed in Bacolla and Wells, 2009). G-rich se-
quences such as telomeres, rDNA, G-rich TRs, as well as CpG
islands can form abnormal DNA structures in vitro referred to
as G-quadruplex (G4) under physiological conditions (reviewed
in Lipps and Rhodes, 2009). These structures form in G-rich374 Cell 143, 367–378, October 29, 2010 ª2010 Elsevier Inc.sequences that contain four tracts of at least three guanines
separated by other bases and are stabilized by G-quartets that
form between four DNA strands held together by Hoogsteen
hydrogen bonds. Such structures are particularly likely to form
when DNA becomes single stranded, for example during replica-
tion and transcription, and may interfere with these nuclear
processes.
To explore the possibility that ATRX targets might form G4
structures in vivo, a genome-wide bioinformatic analysis using
Quadparser was performed to identify regions that have the
potential to form G4 DNA (Huppert and Balasubramanian,
2005). Fifty percent of ATRX peaks were found to overlap with
putative quadruplex sequences (PQSs) (Figure 6A). Given the
difficulty sequencing G-rich repeats and their consequent
contraction in the reference genome, it is possible that PQSs
are under-called in this analysis.
The potential for an ATRX-binding site to form G4 was further
examined using circular dichroism (Paramasivan et al., 2007).
The NME4 TR is predicted to form G4. A 31 bp oligonucleotide
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Figure 6. ATRX Interaction with G-Quadruplex DNA
(A) The proportion of human ATRX ChIP-seq peak coordinates overlapping
with predicted G-quadruplex (G4) forming sequence.
(B) Circular dichroism. The presence of a positive ellipticity maximum at
260 nm and a negative ellipticity minimum at 240 nm suggests a predominantly
parallel G4 form. The small positive ellipticitymaximum at 295 nm is suggestive
of the minor presence of an antiparallel G4 form. See Figure S6A for further
examples of ATRX target sequences forming G4 structures.
(C) Gel-shift assay with recombinant full-length ATRX protein and a [g-32P]ATP
end-labeled G-rich oligonucleotide either preformed into a G4 structure (G4) or
boiled and denatured (D). Reactions contained either 0, 2, or 4 nM rATRX.
Cold competitionwas performedwith a 4-foldmolar excess of either unlabeled
G4 formed oligo (G4), denatured oligo (D), or a Holliday junction (HJ).representing the repeat unit of the NME4 TR was incubated in
conditions that favor G4 DNA formation. The circular dichroism
spectrum was obtained (Figure 6B). A positive ellipticity
maximum was observed at 260 nm and a negative ellipticity
minimum at 240 nm, consistent with a parallel G4 form. Another
smaller ellipticity maximum at 295 nm suggested the coexis-tence of an antiparallel G4 form. A further six ATRX TR target
sequences were analyzed by circular dichroism (CD); the spec-
trographs were consistent with the formation of G4 including
one sequence that was not predicted by Quadparser to form
G4 (Figure S6A and Table S4).
Finally, we used a gel-shift assay to test whether ATRX could
interact with G4 DNA in vitro. A G-rich oligonucleotide was
preformed into G4 DNA, labeled, and incubated with full-length
recombinant ATRX (Figure 6C). ATRX specifically bound to the
G4 structure and no shift was observed when the structure
was denatured by boiling before adding to the binding reaction.
Further, binding to the formed G4 structure can be competed by
a molar excess of unlabeled formed G4 but is less effectively
competed by the denatured G4 oligonucleotide or another
structured nucleic acid (Holliday junction) (Figure 6C), indicating
that ATRX binds the G4 structure rather than the sequence per
se. These data indicate that ATRXmay be recruited to telomeres,
other G-rich TR, and G-rich nonrepetitive DNA and interact with
G-quadruplex DNA.
DISCUSSION
Genome-wide analysis has shown that in euchromatin the
predominant targets of ATRX are sequences containing VNTRs.
Many of these are G and C rich with a high proportion of CpG
dinucleotides. These observations explain why ATRX mutations
affect the a-globin cluster but not the b-globin cluster and cause
a thalassaemia. The a cluster lies in a GC-rich subtelomeric
region containing a high density of CpG islands and G-rich TRs
that we have now shown are targeted by ATRX. The b-globin
cluster has none of these features. It may also explain why in
mouse there are a number of imprinted genes (that are also asso-
ciated with tandemly repeated sequences) whose expression is
affected by downregulation of ATRX (Kernohan et al., 2010).
The relationship between ATRX, VNTRs, and gene expression
is clearly illustrated by the fact that of the targets whose expres-
sion was analyzed, all affected genes were associated with TRs.
Furthermore, at some target genes, the degree by which gene
expression is altered is directly related to the size of the VNTR,
and in the case of one gene examined in detail (NME4), this
can result in monoallelic expression. This provides an explana-
tion for a long-standing question of why individuals with identical
ATRX mutations have variable degrees of a thalassaemia. As
they all have the same mutation and apparently wild-type
a-globin gene clusters, one would have predicted that they
would downregulate the a-globin genes to the same extent.
The highly significant relationship between the effect of the
ATRX deficiency and the natural variation in the VNTR specifi-
cally explains the variable penetrance of ATR-X syndrome but
more importantly identifies a newmechanism that might underlie
many other genetic traits with similar variable penetrance.
A clearly demonstrated but unexplained phenomenon is that,
in the absence of ATRX, expression of the target gene lying
closest to an ATRX peak is the most severely perturbed. How-
ever, adjacent cis-linked genes (up to 10 kb downstream of the
peak) are also affected. For example, although there is enrich-
ment of ATRX across the entire a-globin gene cluster, the main
peak lies close to HBM and is associated with the G-rich TR inCell 143, 367–378, October 29, 2010 ª2010 Elsevier Inc. 375
the HBZ pseudogene. HBM is severely downregulated, but
HBA1 and HBA2 are also downregulated to a lesser degree.
Similarly, at NME4, although this gene is severely downregu-
lated, the adjacent gene (DECR2) is also affected but to a lesser
degree. It appears that ATRX normally binds to these G-rich TRs;
in the absence of ATRX, the repeats at these loci now exert a
repressive influence on transcription that spreads for some
distance from the repeat.
At present it is not clear how ATRX might recognize such
repeat sequences, but one possibility is that they form unusual,
non-B DNA structures in vivo, and in the case of the G-rich
repeats these may take the form of G-quadruplex structures.
Such structures have been demonstrated in vitro using repeats
from telomeres, rDNA, G-rich minisatellites, and CpG-rich
promoters (all ATRX targets), and half of the ATRX targets iden-
tified here are predicted to form G4 DNA. In keeping with the
observations described above, the longer the repeat the more
likely it is to form G4 DNA (Ribeyre et al., 2009). Such structures
have been notoriously difficult to identify in vivo, but the stron-
gest evidence for their existence is at telomeres where it has
been suggested that G4 structures may form during DNA repli-
cation and transcription (Lipps and Rhodes, 2009). It is therefore
of interest that ATRX is recruited to telomeres during replication
and that downregulaton of ATRX by RNAi provokes a DNA-
damage response (marked by gamma-H2AX) at telomeres
during S phase (Wong et al., 2010). Downregulation of ATRX
expression is also associated with an altered expression of
telomere-associated RNA (Goldberg et al., 2010). Both of these
observations would be consistent with ATRX playing a role in
recognizing and/or modifying G4 structures at telomeres and
by implication at other G-rich TRs in vivo. Nevertheless this is
not the only factor determining the localization of ATRX, as at
A/T-rich pericentric heterochromatin, the recruitment of ATRX
depends on the presence of H3K9me3 (Kourmouli et al., 2005).
A role for ATRX at G-rich repeats may also be linked to the
recent observation that ATRX is required for the incorporation
of the histone variant H3.3 at telomeric repeats (Drane´ et al.,
2010; Goldberg et al., 2010; Lewis et al., 2010). H3.3 may be
incorporated into chromatin in a replication-independent or
replication-dependent manner and has typically been found at
actively transcribed regions of the genome and regions of
inherent nucleosome instability where there is a rapid turnover
of histones during interphase (Schneiderman et al., 2009). TRs
with a propensity to form abnormal DNA structures are likely to
be regions of rapid nucleosome turnover. An appealing hypoth-
esis, therefore, is that ATRX influences gene expression by
recognizing unusual DNA configurations at TRs and converting
them to regular forms in part by facilitating incorporation of
H3.3. Consistent with this we find that H3.3 is found at genic
and intergenic ATRX-binding sites, the majority of which are
TRs. However the distribution of H3.3 is only subtly perturbed
at these sites when ATRX is disrupted. One possibility is that
there is a critical requirement for ATRX at a subset of TRs
(such as telomeres), whereas at other sites, other proteins can
intervene. Future studies will focus on determining the role of
ATRX in H3.3 deposition at specific sites.
The role of ATRX may be to recognize unusual forms of DNA
and facilitate their resolution in several contexts. In the absence376 Cell 143, 367–378, October 29, 2010 ª2010 Elsevier Inc.of ATRX, G4 forms may persist and affect many nuclear pro-
cesses including replication, transcription recombination, and
repair.
EXPERIMENTAL PROCEDURES
Western Blotting
For ATRX western blotting, the mouse monoclonal 39c (McDowell et al., 1999)
and rabbit polyclonal H-300 (Insight Biotechnology sc-1540) were used at 1:10
and 1:1000 dilutions, respectively. 23c and 39f recognize an epitope within
ATRX and ATRXt N-terminal to the ADD domain, and H-300 recognizes a
C-terminal epitope within 2193–2492 of full-length ATRX only.
Immunopurification
Nuclear extracts were prepared from wild-type lymphoblastoid cells as previ-
ously described (Dignam, 1990) and incubated overnight at 4C with H-300
antibody crosslinked to protein A-Sepharose. The beads were washed four
times with 20 mM HEPES (pH 7.9), 0.5M KCl, 0.2 mM EDTA, 0.1% Tween,
0.5 mM DTT and immunoprecipitated protein eluted with 0.1 M glycine
(pH 2.5), then neutralized with 1 M KHPO4. A mock immunopurification was
performed as a control in the same way using normal rabbit IgG (Santa Cruz
sc-2027) crosslinked to protein A.
Chromatin Immunoprecipitation
ATRXchromatin immunoprecipitationwas performed according to a published
method (Lee et al., 2006) with the following modifications. Cells were fixed
with 2 mM EGS (Pierce 26103) for 45 min at room temperature in PBS. Form-
aldehyde was then added to 1% for 20 min and quenched with 125 mM
glycine. Chromatin was sonicated to under 500 bp and lysates were immuno-
precipitated with 40 mg ATRX H300 (Insight Biotechnology sc-15408) antibody
or rabbit IgG control (Dako X0903). DNA was precipitated with 20 mg of carrier
glycogen and quantitated using a Qubit fluorimeter (Invitrogen).
Real-Time Q-PCR
Real-time Q-PCR validation of ChIP-seq peaks was performed using SYBR
green mastermix (Applied biosystems 4309155) or using Taqman probes
with a 23 Taq mastermix (Applied Biosystems 4304437). SYBR green primers
(Table S2) were designed using Macvector software and tested by running
a five point, 8-fold serial dilution of genomic DNA to obtain a standard curve
with r2 > 0.99. PCR products were analyzed by melting curve and 3% agarose
gel electrophoresis. Taqman probes were designed using Primer Express
(Applied Biosystems). ChIP enrichments were determined relative to a 3 point
dilution series of input DNA and normalized relative to GAPDH enrichment.
Cell Culture
Human primary erythroblast cultures were prepared using a two-phase liquid
culture system according to a published protocol (Fibach et al., 1991). HbH
inclusions were detected in peripheral blood from ATR-X patients as previ-
ously described (Gibbons et al., 1992). Consent was obtained according to
standard ethics approval guidelines.
Microarray
Fluorescently labeled ChIP and input DNA was analyzed with a custom tiled
microarray covering the subtelomeric region of human chromosome 16p as
previously describe (De Gobbi et al., 2007).
Gene Expression Analysis
RNA was extracted using Tri-reagent (Sigma) and quality checked by micro-
fluidics separation using a 2100 Bioanalyser with an RNA 6000 nano kit
(Agilent 5067-1511). One microgram was reverse transcribed with Superscript
III (Invitrogen). Real-time RT-PCR was performed using commercial Taqman
assays and custom assays. Primer sequences and product codes are listed
in the Extended Experimental Procedures.
High-Throughput Sequencing and Peak Analysis
See Extended Experimental Procedures.
Allelic Discrimination
The ratio of allele-specific transcripts was ascertained with real-time tech-
nology, using an assay designed by Applied Biosystems (Table S2). In brief,
a single amplicon was used, which in combination with two probes, each
specific for one nucleotide of the polymorphism and labeled with a different
fluorophore, allowed quantitation of each species. A standard curve with
known ratios of A:G alleles was used to ensure specificity and quantitativeness
of the assay, and results were confirmed with pyrosequencing (data not
shown). Monoallelic expression is demonstrated with a restriction enzyme
digest assay. The genomic PCR product is 846 bp, of which the G allele
generates fragments of 581 bp and 265 bp when digested with XhoI. The
cDNA PCR product is 854 bp, of which the G allele generates fragments of
563 bp and 291 bp when digested with XhoI. The A allele is undigested by
XhoI in both cases.VNTR Size Measurement
jz VNTR allele lengths were measured in 43 ATR-X patients with a thalas-
saemia by PCR and agarose gel electrophoresis. PCR was performed in
16.6 mM (NH4)2SO4, 67 mM Tris-HCl (pH 8.8), 10% DMSO, 10 mM Beta mer-
captoethanol, 125 mM dNTP, 0.83 mM MgCl2, 0.7 M Betaine, 0.3 ml platinum
Taq (Invitrogen), 250 nM primers 154505F/155293R (Table S2), and 100 to
400 ng genomic DNA in a 60 ml reaction volume. 30 HVR allele sizes were
measured by radio-labeled Southern blotting using AluI digested genomic
DNA and a probe from pa30HVR.64 derived from genomic fragment
Chr16:175999-177279. VNTR sizes were determined with a Typhoon 9400
Variable Mode Imager and ImageQuant TLv2005 software.Circular Dichroism Analysis
An oligonucleotide containing the repeat found within the VNTR of intron 1 of
NME4 (CCGGGGTGGGGGTGGGGGTGTGGGGGGGTGA) was diluted to
2 mM in 20 mM Tris HCl (pH 8) and 5 mM NaCl, heated to 95C for 10 min
then slowly cooled. CD analysis was performed as previously described using
a Jasco 810 CD spectrometer (Giraldo et al., 1994).G4 Gel Shifts
G4 DNA was formed using oligonucleotide OX1-T (containing the Oxytrichia
telomeric repeat sequence) and its structure confirmed as previously
described (Sun et al., 1998). A Holliday junction structure was formed as
previously described (Bachrati and Hickson, 2006). All DNA substrates were
gel-purified prior to use. G4 DNA was labeled with [g-32P]ATP using T4
polynucleotide kinase, and unincorporated nucleotides were removed using
a Sephadex G50 column. Where indicated the G4 probe was boiled for
10 min and quenched on ice to denature the G4 structure. Binding reactions
(10 ml volume) contained 2 fmol of 32P-labeled G4 DNA, full-length rATRX
protein as indicated (0, 20, or 40 fmol), 6 fmol T25 oligonucleotide to minimize
nonspecific binding in a buffer containing 33 mM Tris acetate (pH 7.9), 66 mM
Na acetate, 1 mM MgCl2, 100 mg/ml BSA, and 1 mM DTT. Where indicated,
unlabeled competitor DNA (G4, denatured G4, or Holliday junction) was added
to the reaction at 4-fold molar excess. Reactions were incubated on ice for
30 min. To each reaction 1 ml of 50% glycerol was added and samples were
loaded onto a 5% acrylamide gel and electrophoresed in 0.5 3 TBE at
5 V/cm for 4 hr at 4C. The gel was dried on Whatman filter paper and
visualized by autoradiography.ACCESSION NUMBERS
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